Search

A tough week for markets as concerns over recession, persistent inflation, and geopolitical tensions grow. Explorer stocks were not spared as they all pulled back with exception of Oracle (ORCL) and micro-cap Kraken Robotics (KRKNF). New restrictions on chip-related sales to China hit semiconductor stocks. An almost $8 billion deal by Brookfield Renewable Partners and uranium producer Cameco to buy nuclear services firm Westinghouse is the latest sign of revival in nuclear power after years of decline. The matchup would create something of a Western nuclear powerhouse, pairing a key nuclear power service provider with the largest publicly traded uranium company and one of the world’s biggest owners of wind and solar projects.

This week we sell two positions and go to Japan for a conservative, high quality play on an overlooked but critical part of the electric vehicle revolution.

My career at Cabot began back in June 1999, just before the internet bubble really revved up in October. That was a time of great divergences—the broad market struggled all the way from the mini-bear market bottom of October 1998 right through the top in March 2000. Today I see a similar dichotomy in the market—many “old” leaders are struggling while “new” growth concepts are finding support.

My approach to investing is conservative; the tortoise wins the race. But the race is only won over an extended period of time where cultivating patience is an absolute necessity. My objective is to stay fully invested at all times in stocks and bonds, and only invest in stocks and bonds that will decline a minimal amount during stock market corrections.

Last week, I wrote about the automotive aspects of my recent road trip from Salem to Savannah and back.

The market is at all-time highs, and some think a correction is imminent. Should you still be buying stocks? Our investing experts weigh in.

Want to know the best dividend stocks for 2018? Focus on factors that will attract more investors to the stock short-term. Here are five that fit that mold.

Recent trends in rising oil prices provide plenty of investment opportunities.

As the U.S. economy recovers, M&A activity is picking up steam. You could profit from owning these potential takeover targets.

Mere weeks after its failed merger with Pfizer (PFE), global pharmaceutical company Allergan PLC (AGN), maker of Viagra and Botox, announced a new $10 billion share repurchase authorization. Allergan plans to complete the $40 billion sale of its generic pharmaceutical business to Teva Pharmaceuticals by the end of this month. Following that, Allergan plans to immediately repurchase $4 billion to $5 billion of its stock over the subsequent four to six months. The company also plans to pay down debt with the proceeds of the Teva transaction. Let’s look at the stock’s valuation to see if it’s worth investing in.

We’re seeing a bunch of good-looking setups right now as the combination of the post-election thrust higher and the recent pause has created many favorable charts.

I expect a traders’ market through year end. Be wary: just because a stock rebounds nicely this week does not mean that it will maintain those share price gains.

Patriots quarterback Tom Brady has teamed with with Deckers Outdoor to sell UGGs.

The little stories fill in the blanks behind the government-sanctioned news.

The Federal Reserve event came and passed without much volatility last week as stocks were mostly quiet. For the week the S&P 500 fell 0.5%, the Dow lost 0.2%, and the Nasdaq declined by 0.3%

Given the tumultuous market environment, we wanted to take some time to answer your questions about tariffs, the market, and what to do now.